Treating cells with high doses of IL-2 inhibits cell proliferation, and simultaneous treatments with high doses of IL-2 and anti-CD95 agonist antibodies revert cell inhibition and increase LC3B foci in cervical cancer cells, but do not induce apoptosis. Here, MAP1LC3B is linked to cervical carcinoma.